Neuroscience Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., Jarama 75, 45007-Toledo, Spain.
J Med Chem. 2012 Mar 8;55(5):2388-405. doi: 10.1021/jm2016864. Epub 2012 Feb 24.
The discovery and characterization of compound 48, a selective and in vivo active mGlu2 receptor positive allosteric modulator (PAM), are described. A key to the discovery was the rational exploration of the initial HTS hit 13 guided by an overlay model built with reported mGlu2 receptor PAM chemotypes. The initial weak in vitro activity of the hit 13 was quickly improved, although compounds still had suboptimal druglike properties. Subsequent modulation of the physicochemical properties resulted in compounds having a more balanced profile, combining good potency and in vivo pharmacokinetic properties. Final refinement by addressing cardiovascular safety liabilities led to the discovery of compound 48. Besides good potency, selectivity, and ADME properties, compound 48 displayed robust in vivo activity in a sleep-wake electroencephalogram (sw-EEG) assay consistent with mGlu2 receptor activation, in accordance with previous work from our laboratories.
本文描述了化合物 48 的发现和特征,它是一种选择性和体内有效的 mGlu2 受体正变构调节剂 (PAM)。该发现的关键是基于报告的 mGlu2 受体 PAM 化学型,通过重叠模型对初始高内涵筛选 (HTS) 命中物 13 进行合理探索。命中物 13 的初始体外活性较弱,但很快得到了改善,尽管化合物仍具有不理想的类药性。随后对理化性质进行调节,得到了具有更平衡特征的化合物,兼具良好的效力和体内药代动力学性质。通过解决心血管安全性问题的最终改进,发现了化合物 48。除了良好的效力、选择性和 ADME 特性外,化合物 48 在与 mGlu2 受体激活一致的睡眠-觉醒脑电图 (sw-EEG) 测定中表现出强大的体内活性,这与我们实验室之前的工作相符。